RBC upgrades Lakefront Biotherapeutics stock rating on autoimmune drug potential

🌐 Investing.com (Cyprus) —
RBC upgrades Lakefront Biotherapeutics stock rating on autoimmune drug potential

AI Summary

RBC has upgraded the stock rating for Lakefront Biotherapeutics, citing the potential of a new autoimmune drug. This signals growing investor confidence in the biotechnology sector based on promising pharmaceutical advancements.

Markets Deals Health RBC Lakefront Biotherapeutics stock upgrade biotechnology autoimmune drug pharmaceuticals

Read original source →